BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Abdel Ghafar MT, Morad MA, El-Zamarany EA, Ziada D, Soliman H, Abd-Elsalam S, Salama M. Autologous dendritic cells pulsed with lysate from an allogeneic hepatic cancer cell line as a treatment for patients with advanced hepatocellular carcinoma: A pilot study. Int Immunopharmacol 2020;82:106375. [PMID: 32169808 DOI: 10.1016/j.intimp.2020.106375] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Prince D, Liu K, Xu W, Chen M, Sun JY, Lu XJ, Ji J. Management of patients with intermediate stage hepatocellular carcinoma. Ther Adv Med Oncol 2020;12:1758835920970840. [PMID: 33224278 DOI: 10.1177/1758835920970840] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
2 Chen Z, Lu X, Koral K. The clinical application of camrelizumab on advanced hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2020;14:1017-24. [PMID: 32762583 DOI: 10.1080/17474124.2020.1807939] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
3 Yuan X, Zhang AZ, Ren YL, Wang XL, Jiang CH, Yang L, Liu CX, Liang WH, Pang LJ, Gu WY, Li F, Hu JM. Cytokine-induced killer cells/dendritic cells and cytokine-induced killer cells immunotherapy for the treatment of esophageal cancer: A meta-analysis. Medicine (Baltimore) 2021;100:e24519. [PMID: 33787569 DOI: 10.1097/MD.0000000000024519] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Komatsu S, Fujishima Y, Kido M, Kuramitsu K, Goto T, Yanagimoto H, Toyama H, Fukumoto T. Significant response to atezolizumab plus bevacizumab treatment in unresectable hepatocellular carcinoma with major portal vein tumor thrombus: a case report. BMC Gastroenterol 2021;21:470. [PMID: 34911458 DOI: 10.1186/s12876-021-02053-4] [Reference Citation Analysis]
5 Zhang C, Xu J, Ye J, Zhang X. Prognostic value of HHLA2 expression in solid tumors: A meta-analysis based on the Chinese population. Medicine (Baltimore) 2021;100:e26789. [PMID: 34397730 DOI: 10.1097/MD.0000000000026789] [Reference Citation Analysis]
6 An PP, Feng LN, Zhang XX, Jin QL. Association of interleukin-6 gene polymorphisms with the risk of hepatocellular carcinoma: An up-to-date meta-analysis. Medicine (Baltimore) 2020;99:e23659. [PMID: 33327352 DOI: 10.1097/MD.0000000000023659] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Liu Q, Gao P, Li Q, Xu C, Qu K, Zhang J. Long non-coding RNA SNHG16 as a potential biomarker in hepatocellular carcinoma: A meta-analysis. Medicine (Baltimore) 2021;100:e27178. [PMID: 34516515 DOI: 10.1097/MD.0000000000027178] [Reference Citation Analysis]
8 Ma W, Zhao F, Yu X, Guan S, Suo H, Tao Z, Qiu Y, Wu Y, Cao Y, Jin F. Immune-related lncRNAs as predictors of survival in breast cancer: a prognostic signature. J Transl Med 2020;18:442. [PMID: 33225954 DOI: 10.1186/s12967-020-02522-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
9 Linye H, Zijing X, Wei P, Chao H, Chuan L, Tianfu W. Thymosin alpha-1 therapy improves postoperative survival after curative resection for solitary hepatitis B virus-related hepatocellular carcinoma: A propensity score matching analysis. Medicine (Baltimore) 2021;100:e25749. [PMID: 34011034 DOI: 10.1097/MD.0000000000025749] [Reference Citation Analysis]
10 Shimada S, Kamiyama T, Orimo T, Nagatsu A, Asahi Y, Sakamoto Y, Kamachi H, Taketomi A. Prognoses, outcomes, and clinicopathological characteristics of very elderly patients with hepatocellular carcinoma who underwent hepatectomy. World J Surg Oncol 2020;18:122. [PMID: 32522259 DOI: 10.1186/s12957-020-01899-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
11 Xu B, Sun HC. Camrelizumab: an investigational agent for hepatocellular carcinoma. Expert Opin Investig Drugs 2021;:1-10. [PMID: 34937475 DOI: 10.1080/13543784.2022.2022121] [Reference Citation Analysis]
12 Peng X, He Y, Huang J, Tao Y, Liu S. Metabolism of Dendritic Cells in Tumor Microenvironment: For Immunotherapy. Front Immunol 2021;12:613492. [PMID: 33732237 DOI: 10.3389/fimmu.2021.613492] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Hua H, Wang J, Zhong P, Mou T, Liu P, Xie F. The clinical prognostic value of lncRNA LINC00675 in cancer patients: A meta-analysis. Medicine (Baltimore) 2021;100:e25244. [PMID: 33879657 DOI: 10.1097/MD.0000000000025244] [Reference Citation Analysis]
14 Chen L, Hou Y, Xia Y, Chang L, Diao X, Wang L, Li L, Long Q, Liu Y, Liu Y, Li W. Radiotherapy Dose and Induction Chemotherapy Cycles Are Associated With Prognosis and Toxicity Risk: A Retrospective Study of 227 Patients With Unresectable Stage III Non-Small-Cell Lung Cancer. Technol Cancer Res Treat 2020;19:1533033820951802. [PMID: 33073689 DOI: 10.1177/1533033820951802] [Reference Citation Analysis]